KR102884167B1 - 전립선 특이적 막 항원-발현 암의 진단 또는 치료를 위한 신규한 라디오메탈-결합 화합물 - Google Patents
전립선 특이적 막 항원-발현 암의 진단 또는 치료를 위한 신규한 라디오메탈-결합 화합물Info
- Publication number
- KR102884167B1 KR102884167B1 KR1020207014223A KR20207014223A KR102884167B1 KR 102884167 B1 KR102884167 B1 KR 102884167B1 KR 1020207014223 A KR1020207014223 A KR 1020207014223A KR 20207014223 A KR20207014223 A KR 20207014223A KR 102884167 B1 KR102884167 B1 KR 102884167B1
- Authority
- KR
- South Korea
- Prior art keywords
- cancer
- compound
- psma
- delete delete
- radiometal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
- A61K51/048—DTPA (diethylenetriamine tetraacetic acid)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0485—Porphyrins, texaphyrins wherein the nitrogen atoms forming the central ring system complex the radioactive metal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762575460P | 2017-10-22 | 2017-10-22 | |
| US62/575,460 | 2017-10-22 | ||
| PCT/CA2018/051336 WO2019075583A1 (en) | 2017-10-22 | 2018-10-22 | NOVEL RADIOMETAL BINDING COMPOUNDS FOR THE DIAGNOSIS OR TREATMENT OF CANCER EXPRESSING A PROSTATE-SPECIFIC MEMBRANE ANTIGEN |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20200100043A KR20200100043A (ko) | 2020-08-25 |
| KR102884167B1 true KR102884167B1 (ko) | 2025-11-12 |
Family
ID=66173073
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020207014223A Active KR102884167B1 (ko) | 2017-10-22 | 2018-10-22 | 전립선 특이적 막 항원-발현 암의 진단 또는 치료를 위한 신규한 라디오메탈-결합 화합물 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20200339625A1 (https=) |
| EP (1) | EP3700917A4 (https=) |
| JP (2) | JP7282792B2 (https=) |
| KR (1) | KR102884167B1 (https=) |
| CN (1) | CN111630059B (https=) |
| AU (1) | AU2018352731B2 (https=) |
| CA (1) | CA3079906A1 (https=) |
| WO (1) | WO2019075583A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018204477A1 (en) | 2017-05-02 | 2018-11-08 | Cornell University | Methods and reagents for tumor targeting with greater efficacy and less toxicity |
| SG11202005511VA (en) | 2017-12-13 | 2020-07-29 | Sciencons AS | Complex comprising a psma-targeting compound linked to a lead or thorium radionuclide |
| WO2020210909A1 (en) * | 2019-04-17 | 2020-10-22 | Provincial Health Services Authority | Novel radiolabelled compounds for diagnosis or treatment of prostate-specific membrane antigen-expressing cancer |
| CN110317151B (zh) * | 2019-06-06 | 2022-06-24 | 原子高科股份有限公司 | 前列腺癌PET诊断试剂68Ga-HBBED-ANCP-PSMA及其制备方法和应用 |
| CN114401947B (zh) * | 2019-06-21 | 2024-11-29 | 省卫生服务机构 | 靶向前列腺特异性膜抗原的放射性标记化合物 |
| CA3174082A1 (en) * | 2020-03-04 | 2021-09-10 | Nihon Medi-Physics Co., Ltd. | Compound and radioactive labeling compound |
| US20240018110A1 (en) * | 2020-12-16 | 2024-01-18 | The University Of British Columbia | Radiolabeled compounds targeting the prostate-specific membrane antigen |
| WO2022167681A1 (en) * | 2021-02-08 | 2022-08-11 | Stichting Radboud Universitair Medisch Centrum | Psma-targeting ligands for multimodal applications |
| KR20230154183A (ko) | 2021-03-04 | 2023-11-07 | 니혼 메디피직스 가부시키가이샤 | 화합물 및 방사성 표지 화합물 |
| CN113372285B (zh) * | 2021-05-28 | 2024-06-18 | 西南医科大学附属医院 | 前列腺特异性膜抗原抑制剂、其放射性核素标记物及制法和应用 |
| CN118852044A (zh) | 2021-09-03 | 2024-10-29 | 晶核生物医药科技(南京)有限公司 | 一种肽脲素衍生物、含其的药物组合物及其应用 |
| CN115806529A (zh) * | 2021-09-15 | 2023-03-17 | 威智医药有限公司 | Psma结合剂及其用途 |
| JP2024544870A (ja) * | 2021-11-10 | 2024-12-05 | スージョウ・ルイヘ・メディシン・テクノロジー・カンパニー・リミテッド | Ｐｓｍａ抗原を標的とするリガンド化合物及びそのキレート並びに前立腺癌の診断及び治療のための応用 |
| EP4536278A2 (en) | 2022-06-07 | 2025-04-16 | Actinium Pharmaceuticals, Inc. | Bifunctional chelators and conjugates |
| CN119855612A (zh) * | 2022-09-09 | 2025-04-18 | 同宜医药（苏州）有限公司 | 放射性核素偶联药物及其药物组合物和应用 |
| CN116199736B (zh) * | 2023-03-01 | 2025-03-18 | 西南医科大学附属医院 | 一种DOTA-Te-PSMA化合物及其应用 |
| CN116217505B (zh) * | 2023-03-17 | 2024-10-01 | 南京医科大学 | 用于诊断或治疗表达前列腺特异性膜抗原癌症的新型标记靶向剂 |
| CN116730983B (zh) * | 2023-08-10 | 2023-11-03 | 山东大学 | 一种靶向前列腺特异性抗原的化合物及其制备方法与应用 |
| US20250213705A1 (en) | 2023-08-23 | 2025-07-03 | Bright Peak Therapeutics Ag | Psma targeting ligands and methods of use |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017117687A1 (en) | 2016-01-10 | 2017-07-13 | British Columbia Cancer Agency Branch | 18/19f-labelled compounds which target the prostate specific membrane antigen |
| WO2018215627A1 (en) | 2017-05-24 | 2018-11-29 | ITM Isotopen Technologien München AG | Novel psma-binding agents and uses thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0621973D0 (en) | 2006-11-03 | 2006-12-13 | Philogen Spa | Binding molecules and uses thereof |
| LT4095130T (lt) | 2013-10-18 | 2024-04-25 | Novartis Ag | Žymėti prostatos specifinio membranos antigeno (psma) inhibitoriai, jų naudojimas kaip vizualizavimo medžiagų ir farmacinių medžiagų prostatos vėžiui gydyti |
| EP3544960A1 (en) | 2016-11-23 | 2019-10-02 | Cancer Targeted Technology LLC | Albumin-binding psma inhibitors |
-
2018
- 2018-10-22 US US16/758,361 patent/US20200339625A1/en not_active Abandoned
- 2018-10-22 AU AU2018352731A patent/AU2018352731B2/en active Active
- 2018-10-22 CN CN201880081367.7A patent/CN111630059B/zh active Active
- 2018-10-22 KR KR1020207014223A patent/KR102884167B1/ko active Active
- 2018-10-22 JP JP2020543658A patent/JP7282792B2/ja active Active
- 2018-10-22 CA CA3079906A patent/CA3079906A1/en active Pending
- 2018-10-22 WO PCT/CA2018/051336 patent/WO2019075583A1/en not_active Ceased
- 2018-10-22 EP EP18868855.0A patent/EP3700917A4/en active Pending
-
2023
- 2023-05-17 JP JP2023081323A patent/JP7592120B2/ja active Active
- 2023-07-07 US US18/219,458 patent/US20230348535A1/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017117687A1 (en) | 2016-01-10 | 2017-07-13 | British Columbia Cancer Agency Branch | 18/19f-labelled compounds which target the prostate specific membrane antigen |
| WO2018215627A1 (en) | 2017-05-24 | 2018-11-29 | ITM Isotopen Technologien München AG | Novel psma-binding agents and uses thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| US20230348535A1 (en) | 2023-11-02 |
| JP2023113695A (ja) | 2023-08-16 |
| WO2019075583A1 (en) | 2019-04-25 |
| EP3700917A4 (en) | 2021-08-04 |
| CA3079906A1 (en) | 2019-04-25 |
| CN111630059A (zh) | 2020-09-04 |
| JP7282792B2 (ja) | 2023-05-29 |
| KR20200100043A (ko) | 2020-08-25 |
| EP3700917A1 (en) | 2020-09-02 |
| AU2018352731B2 (en) | 2023-10-05 |
| CN111630059B (zh) | 2025-06-06 |
| US20200339625A1 (en) | 2020-10-29 |
| AU2018352731A1 (en) | 2020-05-21 |
| JP7592120B2 (ja) | 2024-11-29 |
| JP2021503490A (ja) | 2021-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102884167B1 (ko) | 전립선 특이적 막 항원-발현 암의 진단 또는 치료를 위한 신규한 라디오메탈-결합 화합물 | |
| US20240382631A1 (en) | Use of labeled inhibitors of prostate specific membrane antigen (psma), as agents for the treatment of prostate cancer | |
| US11504441B2 (en) | Radiolabeled compounds targeting the prostate-specific membrane antigen | |
| JP6824971B2 (ja) | 前立腺特異的膜抗原（ｐｓｍａ）の１８ｆ−タグ付加インヒビターおよび前立腺癌についての画像化剤としてのその使用 | |
| EP3209336B1 (en) | 18f-tagged inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer | |
| Jackson et al. | 64Cu-NO2A-RGD-Glu-6-Ahx-BBN (7-14) NH2: a heterodimeric targeting vector for positron emission tomography imaging of prostate cancer | |
| JP6661010B2 (ja) | ペプチドチオ尿素誘導体、これを含有する放射線同位体標識化合物、およびこれを活性成分として含有する前立腺癌を処置または診断するための医薬組成物 | |
| US12472272B2 (en) | Radiolabelled compounds for diagnosis or treatment of prostate-specific membrane antigen- expressing cancer | |
| US20240342321A1 (en) | Novel cxcr4-targeting compounds | |
| US20220133919A1 (en) | ONE STEP 64Cu-BaBaSar-RGD2 PRODUCTION METHOD | |
| Zheng et al. | Comparison of biological properties of 111In-labeled dimeric cyclic RGD peptides | |
| Kim et al. | Evaluation of a 64Cu-labeled 1, 4, 7-triazacyclononane, 1-glutaric acid-4, 7 acetic acid (NODAGA)-galactose-bombesin analogue as a PET imaging probe in a gastrin-releasing peptide receptor-expressing prostate cancer xenograft model | |
| JP2026506464A (ja) | 部位特異的ｕＰＡＲ標的化のための放射性核種標識ペプチドコンジュゲート | |
| JP2015083546A (ja) | 癌の原発巣・骨転移の検査・治療用放射性標識薬剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| Q13 | Ip right document published |
Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE) |